Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyopen access
- Authors
- Bahlis, NJ[Bahlis, Nizar J.]; Dimopoulos, MA[Dimopoulos, Meletios A.]; White, DJ[White, Darrell J.]; Benboubker, L[Benboubker, Lotfi]; Cook, G[Cook, Gordon]; Leiba, M[Leiba, Merav]; Ho, PJ[Ho, P. Joy]; Kim, K[Kim, Kihyun]; Takezako, N[Takezako, Naoki]; Moreau, P[Moreau, Philippe]; Kaufman, JL[Kaufman, Jonathan L.]; Krevvata, M[Krevvata, Maria]; Chiu, C[Chiu, Christopher]; Qin, X[Qin, Xiang]; Okonkwo, L[Okonkwo, Linda]; Trivedi, S[Trivedi, Sonali]; Ukropec, J[Ukropec, Jon]; Qi, M[Qi, Ming]; San-Miguel, J[San-Miguel, Jesus]
- Issue Date
- Jul-2020
- Publisher
- NATURE PUBLISHING GROUP
- Citation
- LEUKEMIA, v.34, no.7, pp.1875 - 1884
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA
- Volume
- 34
- Number
- 7
- Start Page
- 1875
- End Page
- 1884
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/7650
- DOI
- 10.1038/s41375-020-0711-6
- ISSN
- 0887-6924
- Abstract
- In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are presented. Patients (N = 569) with >= 1 prior line received Rd (lenalidomide, 25 mg, on Days 1-21 of each 28-day cycle; dexamethasone, 40 mg, weekly) +/- daratumumab at the approved dosing schedule. Minimal residual disease (MRD) was assessed by next-generation sequencing. After 44.3 months median follow-up, D-Rd prolonged progression-free survival (PFS) in the intent-to-treat population (median 44.5 vs 17.5 months; HR, 0.44; 95% CI, 0.35-0.55; P < 0.0001) and in patient subgroups. D-Rd demonstrated higher ORR (92.9 vs 76.4%; P < 0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; P < 0.0001) and MRD negativity (10(-5); 30.4 vs 5.3%; P < 0.0001). Median time to next therapy was prolonged with D-Rd (50.6 vs 23.1 months; HR, 0.39; 95% CI, 0.31-0.50; P < 0.0001). Median PFS on subsequent line of therapy (PFS2) was not reached with D-Rd versus 31.7 months with Rd (HR, 0.53; 95% CI, 0.42-0.68; P < 0.0001). No new safety concerns were reported. These data support using D-Rd in patients with RRMM after first relapse.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.